Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Aerosols (1)
- Animals (1)
- Antigens (1)
- Antigens, Polyomavirus Transforming (1)
- Blood Pressure (1)
-
- Cell Division (1)
- Cell Transformation (1)
- Cell Transformation, Neoplastic (1)
- Child (1)
- Child, Preschool (1)
- Congenital (1)
- Heart Defects (1)
- Heart Defects, Congenital (1)
- Humans (1)
- Hyperplasia (1)
- Hypertension (1)
- Hypertension, Pulmonary (1)
- IGF Type 1 (1)
- Infant (1)
- Insulin-Like Growth Factor Binding Protein 3 (1)
- Insulin-Like Growth Factor II (1)
- Liver Neoplasms (1)
- Messenger (1)
- Metalloendopeptidases (1)
- Mice (1)
- Mice, Transgenic (1)
- Neoplastic (1)
- Nitroglycerin (1)
- Phosphorylation (1)
- Polyomavirus Transforming (1)
Articles 1 - 2 of 2
Full-Text Articles in Medical Specialties
Insulin-Like Growth Factor Ii Signaling In Neoplastic Proliferation Is Blocked By Transgenic Expression Of The Metalloproteinase Inhibitor Timp-1, David C. Martin, John L. Fowlkes, Bojana Babic, Rama Khokha
Insulin-Like Growth Factor Ii Signaling In Neoplastic Proliferation Is Blocked By Transgenic Expression Of The Metalloproteinase Inhibitor Timp-1, David C. Martin, John L. Fowlkes, Bojana Babic, Rama Khokha
Pediatrics Faculty Publications
Insulin-like growth factor (IGF) II is overexpressed in many human cancers and is reactivated by, and crucial for viral oncogene (SV40 T antigen, [TAg])-induced tumorigenesis in several tumor models. Using a double transgenic murine hepatic tumor model, we demonstrate that tissue inhibitor of metalloproteinase 1 (TIMP-1) blocks liver hyperplasia during tumor development, despite TAg-mediated reactivation of IGF-II. Because the activity of IGFs is controlled by IGF-binding proteins (IGFBPs), we investigated whether TIMP-1 overexpression altered the IGFBP status in the transgenic liver. Ligand blotting showed that IGFBP-3 protein levels were increased in TIMP-1-overexpressing double transgenic littermates, whereas IGFBP-3 mRNA levels were …
Nebulized Nitroglycerin In Children With Pulmonary Hypertension Secondary To Congenital Heart Disease, Hatim Omar, Fangqi Gong, Mei Y. Sun, Stanley Einzig
Nebulized Nitroglycerin In Children With Pulmonary Hypertension Secondary To Congenital Heart Disease, Hatim Omar, Fangqi Gong, Mei Y. Sun, Stanley Einzig
Pediatrics Faculty Publications
Pulmonary hypertension continues to be a major cause of morbidity and mortality, despite new treatments. Since inhaled nitric oxide has been reported to be effective in some cases, we investigated using nebulized nitroglycerine to treat pulmonary hypertension in children with congenital heart disease. Four children (ages 6-72 months) with severe pulmonary hypertension secondary to congenital heart disease (all with membranous ventricular septal defect, undergoing cardiac catheterization) were given 3 cc of nebulized normal saline over 10 min as placebo control, followed by nebulized nitroglycerine (20 micrograms/Kg in 3 cc normal saline). Normal saline administration did not elicit any change, but …